Background/Aims Biliary tract cancer (BTC) frequently harbors KRAS mutations, which are associated with resistance to traditional treatment and a poor prognosis. Synthetic lethality (SL) strategy may provide other targets of KRAS. Therefore, we aim to identify and validate potential therapeutic targets of KRAS for the treatment of BTC via SL.
Methods The dependency (DepMap) projects were used to predict the synthetic lethal gene of KRAS. FDA-approved anticancer drug library was applied to screen potential drugs effective against KRAS-mutant BTC. Furthermore, the synthetic lethal effects or corresponding mechanisms of potential genes and drugs on BTC were investigated using KRAS-mutant and KRAS-wild type BTC cell lines, patient-derived xenografts (PDX), and KRAS oncogene-driven tumor models, as well as other KRAS-mutant cancer cell lines.
Results Initially, we discovered that the loss of GATA2 reduced the viability of KRAS-mutant but not KRAS-wild-type BTC. Subsequently, the drug library screened out disulfiram, which primarily exerts a synthetic lethal effect by inhibiting interleukin-1β (IL-1β) in KRAS-mutant BTC. Mechanistically, GATA2 specifically enhanced the transcription of IL-1β to promote NF-κB signaling in KRAS-mutant BTC. IL-1β inhibition phenocopied GATA2 deficiency, leading to reduced KRAS-mutant BTC viability. These synthetically lethal effects were confirmed using PDX, a KRAS oncogene-driven tumor model, as well as in other KRAS-mutant cancer cell lines.
Conclusions In summary, these results indicate that inhibiting GATA2/IL1β could be a therapeutic strategy in KRAS-mutant BTC and potentially other cancers.
Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak Journal of Korean Medical Science.2026;[Epub] CrossRef
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Gut and Liver.2026; 20(4): 636. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Liver fibrosis is a chronic liver injury resulting from factors like viral hepatitis, autoimmune hepatitis, non-alcoholic steatohepatitis, fatty liver disease, and cholestatic liver disease. Liver transplantation is currently the gold standard for treating severe liver diseases. However, it is limited by a shortage of donor organs and the necessity for lifelong immunosuppressive therapy. Mesenchymal stem cells (MSCs) can differentiate into various liver cells and enhance liver function when transplanted into patients due to their differentiation and proliferation capabilities. Therefore, it can be used as an alternative therapy for treating liver diseases, especially for liver cirrhosis, liver failure, and liver transplant complications. However, due to the potential tumorigenic effects of MSCs, researchers are exploring a new approach to treating liver fibrosis using extracellular vesicles (exosomes) secreted by stem cells. Many studies show that exosomes released by stem cells can promote liver injury repair through various pathways, contributing to the treatment of liver fibrosis. In this review, we focus on the molecular mechanisms by which stem cell exosomes affect liver fibrosis through different pathways and their potential therapeutic targets. Additionally, we discuss the advantages of exosome therapy over stem cell therapy and the possible future directions of exosome research, including the prospects for clinical applications and the challenges to be overcome.
Citations
Citations to this article as recorded by
Altered mRNA and protein expression of exosome-related markers in bile duct ligation-induced liver fibrosis in rats Khalil Hajiasgharzadeh, Fatemeh Pashazadeh, Mohammad Reza Alipour, Reza Rahbarghazi, Maryam Shoaran, Mahdi Ahmadi Tissue and Cell.2027; 104: 103909. CrossRef
Sarcopenia and MASLD: novel insights and the future Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng Nature Reviews Endocrinology.2026; 22(3): 139. CrossRef
The Potential of Neural Stem Cell-derived Exosomes for the Treatment of Ischemic Stroke Xu Deng, Xixiang Xie, Tao Zhu, Chunxia Chen Stem Cell Reviews and Reports.2026; 22(2): 803. CrossRef
Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu Journal of Immunology Research.2026;[Epub] CrossRef
Modulation of PRL-1 in placental MSCs: A novel therapeutic strategy for hepatic fibrosis: Editorial on “Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal t Lihai Jiang, Wenjie Zheng Clinical and Molecular Hepatology.2026; 32(1): 377. CrossRef
Liver Fibrosis: Current Treatments, Bottlenecks, and Future Prospects for Translational Medicine Dileep G. Nair, Ralf Weiskirchen Sci.2026; 8(1): 9. CrossRef
Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng Journal of Translational Internal Medicine.2026; 14(1): 134. CrossRef
Exosome/vancomycin enable targeted therapeutics of liver abscess with enhanced anti-inflammation performance Yaoqian Huangfu, Bolun Yang, Xiaolu Hao, Jifeng Wang, Yong Liu, Juanjuan Li TransMed.2026; 1(1): 100010. CrossRef
Good Manufacturing Practice-Derived Human Liver Stem Cell Extracellular Vesicles Attenuate Liver Fibrosis In Vivo Elena Ceccotti, Veronica Dimuccio, Chiara Pasquino, Massimo Cedrino, Maria Beatriz Herrera Sanchez, Cristina Grange, Federico Figliolini, Giorgio Nicolò, Federica Antico, Selene Limoncelli, Giulio Mengozzi, Giulia Gioiello, Marta Tapparo, Fabio Cattelino, Cells.2026; 15(8): 661. CrossRef
Recent advances in engineered exosomes for targeted microRNA delivery to reverse liver fibrosis Sara Mohammadi Miyanroodan, Muhammad Sohail Journal of Drug Delivery Science and Technology.2026; 122: 108447. CrossRef
Clinical translational research on stem cell products: prospects and challenges Shuang Chen, Lin Zhang, Yushuang Ren, Xue Bai, Xiao Wei, Maoyue Chai, Susu Cui, Xinran Zhao, Hongxin Deng Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases Chuyang Meng, Min Liu, Qianqian Qi, Lixue Cao, Qi Lei, Xifu Liu, Meng Wang International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Mesenchymal stem cells in intrahepatic and extrahepatic biliary diseases: mechanisms and therapeutic applications Meng-jiao Li, Wei Zhao, Cai-yang Li, Yan-ling Li, Shi-hui Ren, Jia-jia Li, Ling Qiu, Cheng-wei Yang, Fang-yi Fan, Hao Yao Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Natural Flavonoids as Potential Modulators of Liver Fibrosis: A Review of Mechanisms and Therapeutic Targets Jia Liu, Yi Han, Lingli Chen, Yifei Chen, Haiping Liang, Hui Chen, Wenbing Hu, Suyun Lin, Wenjun Wang Journal of Future Foods.2026;[Epub] CrossRef
How Physiology and Pharmacology Shape Liver Regeneration: From Molecules and Cells to Trials Amedeo Lonardo, Ralf Weiskirchen International Journal of Molecular Sciences.2026; 27(13): 5967. CrossRef
Application of exosomes derived from mesenchymal stem cells in osteoarthritis Qianying Feng, Ruixue Liu, Shitian Feng, Dan Li, Sen Wang, Huigen Feng, Junzheng Yang Journal of Orthopaedic Surgery and Research.2026;[Epub] CrossRef
Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases Daifei Shen, Runji Chen, Shu Ye Research.2026;[Epub] CrossRef
miR-26b-modified human umbilical cord mesenchymal stem cells exhibit enhanced anti-fibrotic efficacy in a mouse model of hepatic fibrosis Jianwei Xu, Lihong He, Jingxia Xu, Xiuzhen Yang, Wanhang Deng, Can Liu, Li Yuan, Xuxian Wu, Huanxiang Zhang Molecular Biology Reports.2026;[Epub] CrossRef
The therapeutic potential of different mesenchymal stem cells and their derived exosomes in metabolic dysfunction-associated steatotic liver disease Dan Qin, Pingping Huang, Jialing Chen, Changjun Wu, Yuzhen Liang Frontiers in Endocrinology.2025;[Epub] CrossRef
Stem cells therapies for liver diseases: for current practice and future goals Yunbo Xie, Ziying Zhang, Yuefei Pan, Fu-Sheng Wang Hepatology International.2025; 19(5): 1051. CrossRef
Human Umbilical Cord Blood Plasma‐Derived Exosomal miR‐410‐3p Alleviates Liver Injury by Regulating the Mitochondria‐Mediated Antiapoptotic Signaling Lin Zhang, Yushuang Ren, Dongsheng Su, Qingyuan Jiang, Huan Peng, Fuyi Cheng, Hantao Zhang, Xue Bai, Xiao Wei, Weixiao Yang, Pusong Zhao, Yixin Ye, Gang Shi, Hongxin Deng MedComm.2025;[Epub] CrossRef
Exosome Carrying OCT4/miR‐1246/β‐catenin Deriving From HBV Infected Hepatocytes Accelerated Liver Fibrosis Tiantian Zhu, Yuankun Chen, Mingyue Niu, Qionghan He, Minhua Weng, Zheng Wang, Wenting Li Journal of Biochemical and Molecular Toxicology.2025;[Epub] CrossRef
Integrating Network Pharmacology, Molecular Docking, and Experimental Validation: Andrographolide Attenuates Acute Liver Injury via the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway Yankun Zhang, Shuanghui Liu, Xiaoxia Liang, Lizi Yin, Changliang He Biomolecules.2025; 15(12): 1743. CrossRef
Cell-specific roles of autophagy in liver fibrosis: implications for targeted pharmacotherapy Chibo Liu, Huan Yang, Yongjie Liu, Min An, Zhiyong Weng, Lihua Li Annals of Medicine.2025;[Epub] CrossRef
Backgrounds/Aims Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol can prevent hepatic decompensation in patients with high-risk CSPH stratified using the new model.
Methods Non-invasive risk factors of CSPH were identified via systematic review and meta-analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new non-invasive model was validated for various performance aspects in three cohorts, i.e., a multicenter HVPG cohort, a follow-up cohort, and a carvediloltreating cohort.
Results In the meta-analysis with six studies (n=819), liver stiffness measurement and platelet count were identified as independent risk factors for CSPH and were used to develop the new “CSPH risk” model. In the HVPG cohort (n=151), the new model accurately predicted CSPH with cutoff values of 0 and –0.68 for ruling in and out CSPH, respectively. In the follow-up cohort (n=1,102), the cumulative incidences of decompensation events significantly differed using the cutoff values of <–0.68 (low-risk), –0.68 to 0 (medium-risk), and >0 (high-risk). In the carvediloltreated cohort, patients with high-risk CSPH treated with carvedilol (n=81) had lower rates of decompensation events than non-selective beta-blockers untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=162 after PSM).
Conclusions Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.
Citations
Citations to this article as recorded by
Machine learning-based prediction models for liver-related events in patients with hepatitis B-related cirrhosis and clinically significant portal hypertension Yan-Qiu Li, Zhuo-Jun Li, Yong-Qi Li, Ying Feng, Xian-Bo Wang World Journal of Gastroenterology.2026;[Epub] CrossRef
Carvedilol Versus Endoscopic Variceal Ligation for Prophylaxis of Esophageal Variceal Bleeding in Patients With Liver Cirrhosis Luiz G.S. Almeida, Ocílio R. Gonçalves, Thiago H.F. de Oliveira, João V. Andrade Fernandes, Hildel F.L. Filho, Maria J.G. Siqueira, Paweł Łajczak, Wagner Rios-Garcia, Jefferson H. Marques Fontes, Lucas L. Mendes, Marcos de Vasconcelos Carneiro Journal of Clinical Gastroenterology.2026; 60(7): 569. CrossRef
Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial Yiling Li, Li Du, Shuairan Zhang, Chuan Liu, Chao Ma, Xiaochao Liu, Huanhai Xu, Zhixu Fan, Shengjuan Hu, Jing Wang, Lichun Shao, Lijun Peng, Huiling Xiang, Xuan Liang, Wenhui Zhang, Hongyun Zhao, Pengyuan He, Jingyi Xu, Qianlong Li, Ling Yang, Yunhai Wu, BMJ Open.2025; 15(4): e093866. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Revolutionising portal hypertension diagnosis: the rise of non-invasive techniques in liver cirrhosis Bocheng Gao, Yumeng Lin, Huimin Zhang, Yulin Li, Shuhua Gou, Peiling Ma, Xueni Zhao, Yue Zhou, Qian Chen, Lan Yuan, Zhongyu Han, Chang Yu Frontiers in Medicine.2025;[Epub] CrossRef
Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis? Ling Yang, Chuan Liu, Jimmy Che‐To Lai, Xiaolong Qi Alimentary Pharmacology & Therapeutics.2024; 60(7): 965. CrossRef
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song Clinical and Molecular Hepatology.2025; 31(2): e128. CrossRef
Background/Aims Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients.
Methods We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment.
Results We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all p≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, p<0.0001).
Conclusions IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, J Alimentary Pharmacology & Therapeutics.2026; 63(3): 374. CrossRef
Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy Yu Jun Wong Alimentary Pharmacology & Therapeutics.2026; 63(4): 574. CrossRef
Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie Journal of Viral Hepatitis.2026;[Epub] CrossRef
Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune Archives of Virology.2026;[Epub] CrossRef
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong Clinical and Molecular Hepatology.2026; 32(1): 429. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnostic value of transient elastography in assessing the degree of liver fibrosis in chronic hepatitis B patients with low alanine aminotransferase levels and concomitant hepatic steatosis Aili Wang, Qingqing Wang, Huaie Liu Saudi Journal of Gastroenterology.2026; 32(3): 214. CrossRef
Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id Heejoon Jang, Won Kim Clinical and Molecular Hepatology.2026; 32(1): 426. CrossRef
Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Rui Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(1): e85. CrossRef
Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study Xiao-hao Wang, Yu-nan Chang, Lu Zhang, Yan-li Yang, Lu-wen Liang, Yi Zeng, Zhi Zhou, Shan Zhong, Hu Li Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita Diabetic Medicine.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis George Papatheodoridis, Vasileios Lekakis, Rafael Esteban, Maria Buti Clinics in Liver Disease.2026; 30(2): 557. CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Correlation analysis of Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B patients Chun Yu, Meiling Chen, Xiaonan Han, Yuhang Feng, Hongwei Sun, Hong Yang Journal of Medical Biochemistry.2026; 45(4): 749. CrossRef
Multimorbidity patterns and their associations with healthcare services utilisation in inpatients with chronic hepatitis B infection from 2011 to 2023: a retrospective observational study Xu Wang, Jinzhao Xie, Yuankai Wu, Guanzi Chen, Huiyu Ao, Zifeng Liu, YuSheng Jie, Jing Gu BMJ Open.2026; 16(4): e106218. CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease Chieh Liu, Yi-Fen Shih, Chun-Jen Liu Clinical and Molecular Hepatology.2026; 32(2): 565. CrossRef
Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis Jarell Jie-Rae Tan, Ellina Lytvyak, Joo Wei Ethan Quek, Corrine Lee Singh, Yuan Jie Aidan Low, Shi Jie Ong, Mark Muthiah, Yu Jun Wong, Aldo J. Montano-Loza Hepatology Communications.2026;[Epub] CrossRef
What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol Emily Martyn, Jessica Carter, Maeve Barlow, Flora Olcott, Indrajit Ghosh, Elizabeth Waddilove, Alejandro Arenas-Pinto, Richard Gilson, Stuart Flanagan, WD Francois Venter, Jennifer Manne-Goehler, Sally Hargreaves, Emmanouil Tsochatizis, Douglas MacDonald, Wellcome Open Research.2026; 11: 285. CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Concomitant Liver Steatosis in Chronic Hepatitis B Virus Infection Is Linked to a Distinct Cytokine Profile and Reduced Viral Load Katharina John, Marie-Louise Voss, Sherin Al Aoua, Martin Franck, Christine S Falk, Heiner Wedemeyer, Klaus Schulze-Osthoff, Heike Bantel The Journal of Infectious Diseases.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease Ningxin Zhang, Zhongwei Xu, Fei Lin, Haozhi Fan, Dehong Zhou, Shiqiu Zheng, Peng Jin, Huiquan Gu, Chengxiao Yu, Longfeng Jiang Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Steatotic liver disease in autoimmune liver disease: Prevalence and clinical impact in a Southeast Asian cohort Jarell Jie-Rae Tan, Shwetha Thiyagarajan, Jessica Tan, Jeannie Ong, Kenneth Lin, Chin-Hock Nicholas Tee, Chin Kimg Tan, Andrew Tan, Daphne Ang, Tiing Leong Ang, Andrew Kwek, Yu Jun Wong Canadian Liver Journal.2026; 9(3): 432. CrossRef
Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong Liver International.2026;[Epub] CrossRef
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes George Papatheodoridis, Maria Buti, Yusuf Yilmaz, Ming‐Lung Yu, Mohamed El‐Kassas, Khalid Alswat, Marlen Ivon Castellanos Fernandez, Yuichiro Eguchi, Ajay Duseja, Caglayan Keklikkiran, Saeed Hamid, Wah Kheong Chan, Stuart C. Gordon, Stuart K. Roberts, Jac Journal of Gastroenterology and Hepatology.2026; 41(8): 2440. CrossRef
What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol Emily Martyn, Jessica Carter, Maeve Barlow, Flora Olcott, Indrajit Ghosh, Elizabeth Waddilove, Alejandro Arenas-Pinto, Richard Gilson, Stuart Flanagan, WD Francois Venter, Jennifer Manne-Goehler, Sally Hargreaves, Emmanouil Tsochatizis, Douglas MacDonald, Wellcome Open Research.2026; 11: 285. CrossRef
MASLD In PBC: A Shift From Liver‐Centred to Cardiometabolic Risk Assessment? Francesca Colapietro, Mauro Viganò Liver International.2026;[Epub] CrossRef
The “viral–metabolic” interaction mechanisms and management challenges in chronic hepatitis B combined with metabolic dysfunction-associated fatty liver disease: from clinical evidence to an integrated multidisciplinary framework Qianqian Zhu, Chengde Su, Qiaoqiao Yao, Ting Yang, Yali Xu, Mingdan Li, Qian Liu, Yawen Luo, Ping Yang Frontiers in Immunology.2026;[Epub] CrossRef
Obesity management for the hepatologist—What to do, how to do it and why? Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, Mohammad Siddiqui, Jenny Lam, Tayyab S. Diwan, Michael Camilleri Hepatology.2025; 81(5): 1607. CrossRef
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao American Journal of Gastroenterology.2025; 120(2): 401. CrossRef
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao Cancer.2025;[Epub] CrossRef
Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history Wen-Jie Liu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu Journal of Gastroenterology.2025; 60(1): 107. CrossRef
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao Journal of Hepatology.2025; 83(1): 43. CrossRef
The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines Grace Lai-Hung Wong, Maud Lemoine Journal of Hepatology.2025; 82(5): 918. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao The Journal of Infectious Diseases.2025; 232(2): 474. CrossRef
Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, Frank Mulindwa, Mackenzie G. Cater, Robert A. Salata, Jeffrey M. Jacobson Frontiers in Immunology.2025;[Epub] CrossRef
Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID) Zhenqiu Liu, Yanfeng Jiang, Chen Suo, Huangbo Yuan, Ziyu Yuan, Tiejun Zhang, Li Jin, Xingdong Chen International Journal of Epidemiology.2025;[Epub] CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo Journal of Hepatology.2025; 83(2): 502. CrossRef
Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, Fernando Bessone, Margarita Anders, Mario G. Pessoa, Fernando Cairo, D Journal of Viral Hepatitis.2025;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats Clinical and Molecular Hepatology.2025; 31(3): 1003. CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, Carmen Chak-Lui Wong, Valerie Chew, Bryan Cho Wing Li, Roland Leung, Tan To Cheung, Thomas Yau Liver Cancer.2025; 15(3): 480. CrossRef
Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review Rushi V. Mukkawar, Nishant Rathod, Rajvardhan Patil, Sunil Kumar, Sourya Acharya International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 368. CrossRef
Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun Cancers.2025; 18(1): 120. CrossRef
Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise? Xiaoming Xu, Mindie H. Nguyen, Jie Li Clinical Gastroenterology and Hepatology.2024; 22(9): 1956. CrossRef
Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study Shanshan Qin, Jing Wang, Haiqing Yuan, Jingzhen He, Shoujing Luan, Yan Deng Frontiers in Genetics.2024;[Epub] CrossRef
The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy Frontiers in Gastroenterology.2024;[Epub] CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert J. de Knegt, Qiuwei Pan Hepatology International.2024; 18(3): 1053. CrossRef
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Journal of Gastroenterology and Hepatology.2024; 39(6): 1190. CrossRef
Impact of metabolic disorders on chronic hepatitis B Shang-Chin Huang, Chun-Jen Liu, Jia-Horng Kao Clinical Liver Disease.2024;[Epub] CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef
Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database David Uihwan Lee, Kuntal Bhowmick, Sindhura Kolachana, Kimberly Schuster, Aneesh Bahadur, Ashton Harmacinski, Sophie Schellhammer, Gregory Hongyuan Fan, Ki Jung Lee, Catherine Sun, Hannah Chou, Zurabi Lominadze Digestive Diseases and Sciences.2024; 69(7): 2401. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Exploration of Digestive Diseases.2024; : 175. CrossRef
Liver health in hemophilia in the era of gene therapy Yesim Dargaud, Massimo Levrero, François Bailly, Anne Lienhart, Fabien Zoulim Thrombosis Research.2024; 240: 109064. CrossRef
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong eClinicalMedicine.2024; 74: 102727. CrossRef
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu Hepatology International.2024; 18(S2): 897. CrossRef
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’ Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe Canadian Liver Journal.2024; 7(3): 385. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng World Journal of Hepatology.2024; 16(12): 1395. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B Xianhua Mao, Lung Yi Mak, Wai-Kay Seto Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease Yajing You, Tao Yang, Shuhang Wei, Zongxin Liu, Chenxi Liu, Zijian Shen, Yinuo Yang, Yuemin Feng, Ping Yao, Qiang Zhu Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2283. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
Persistent steatosis correlates with decreased fibrosis regression during anti‐HBV treatment in patients with chronic HBV infection Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong, Gwyneth Shook Ting Soon, Xiaojuan Ou, Jidong Jia, Wei Chen, Yameng Sun, Hong You Journal of Medical Virology.2023;[Epub] CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
First
Prev
